Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
VICTOR Robert DEFILIPPIS · OREGON HEALTH & SCIENCE UNIVERSITY · 2022 · $787,088 — PROJECT SUMMARY The goals of this R01 proposal include the molecular and immunological characterization of vaccine adjuvant activity associated with processes mediated by the protein Stimulator of Interferon Genes (STING). Two vital insufficiencies are currently evident regarding adjuvanted human va…
Barton F. Haynes · DUKE UNIVERSITY · 2022 · $3,878,223 — While HIV-1 broadly neutralizing antibodies (bnAbs) provide potent protection from HIV-1, to date they have been difficult to induce in the setting of vaccination. A second type of HIV-1 envelope (Env) antibodies that are easy to induce are termed non-neutralizing antibodies (NNAbs) (because they ar…
Kay Lynn Medina · MAYO CLINIC ROCHESTER · 2022 · $318,000 — PROJECT SUMMARY Steady-state hematopoiesis in bone marrow is critical for maintenance of blood cell genesis and immune competence throughout life. Concomitant with aging, the bone marrow hematopoietic stem cell (HSC) compartment undergoes cell intrinsic and extrinsic changes that biases hematopoieti…
David A. Hafler · YALE UNIVERSITY · 2022 · $2,874,261 — ABSTRACT We propose a deep interrogation and a systems approach that will identify molecular signatures to vaccination across three cohorts of vulnerable patient populations: autoimmune patients with B cell depletion, aged and frail individuals, and patients with sickle cell disease who are functio…
JOSHUA ALAN CHOE · UNIVERSITY OF WISCONSIN-MADISON · 2022 · $37,443 — PROJECT SUMMARY / ABSTRACT Age related traumatic and pathologic fractures are expected to increase greatly in incidence in the coming decades with aging populations. Older patients are at higher risk for non-healing, ‘critical-size’, bone defects following fracture. This is exacerbated in composite …
Ross M Kedl · UNIVERSITY OF COLORADO DENVER · 2022 · $233,250 — Project summary. Clinically relevant cellular responses to either experimental or FDA approved vaccine adjuvant formulations have been difficult to generate and/or detect. We have long been investigating a combined adjuvant formulation (composed of a TLR agonist and an agonistic antiCD40 antibody) w…
Z Hong ZHOU · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $456,167 — Double-stranded RNA (dsRNA) viruses comprise a large group of non-enveloped viruses characterized by their ability to transcribe their RNA within an intact capsid (i.e., endogenous RNA transcription), thus evading cellular antiviral responses to dsRNA. Among them, members of the Reoviridae family of…
Joel H Collier · DUKE UNIVERSITY · 2022 · $435,245 — Even when vaccines are rapidly developed and shown to be efficacious and safe, vaccination campaigns continue to be hampered by public hesitancy and by challenges distributing vaccines equitably around the globe. Vaccine hesitancy, where individuals refuse or delay vaccination, has been a persistent…
Robbie B Mailliard · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2022 · $781,490 — ABSTRACT The CDC recommends that persons living with HIV (PWH) be vaccinated against SARS-CoV-2. However, there are minimal scientific data to support this important public health principle in relation to ongoing immune dysfunction and chronic comorbidities and the persistent HIV reservoir in antire…
MATTHEW TIRRELL · UNIVERSITY OF CHICAGO · 2022 · $797,003 — Project Summary This R01 proposal outlines a research plan which uses targeted nanomedicine to enhance disease- modifying molecular mechanisms both in the acute injurious phase and in the subsequent chronic fibrotic phase of viral-induced pneumonitis. The overall goal of this proposal is to use nan…
STEVEN GREGORY REED · HDT BIO CORPORATION · 2022 · $550,719 — PROJECT SUMMARY/ABSTRACT Our team - in collaboration with other vaccine developers - has been actively involved in tuberculosis (TB) vaccine discovery for the past three decades and led the team that developed the M72 vaccine that has provided proof of concept for effective subunit TB vaccines. Obst…
Denise L. Doolan · JAMES COOK UNIVERSITY OF NO QUEENSLAND · 2022 · $495,904 — PA-19-077 DOOLAN: PROJECT SUMMARY Malaria remains a global public health problem with nearly half of the world's population at risk. An effective malaria vaccine would prevent almost half a million deaths and over 200 million clinical cases each year and help eradicate the disease. The most effectiv…
Sarah Elizabeth Walker · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2022 · $300,345 — SUMMARY: The level of each protein synthesized in a cell results from both the amount of mRNA available, and the number of ribosomes that initiate translation of that mRNA. Eukaryotic translation initiation factors (eIFs) can reprogram which mRNAs are available and translated to produce different le…
Asok Antony · RLR VA MEDICAL CENTER · 2022 — Despite the advent of effective anti-Human Papillomavirus (HPV) vaccines, there are no biological agents to reliably prevent ~80 million Americans from transmitting their infectious HPV viral particles to sexual partners. Earlier we determined that the post-translational homocysteinylation of an mR…
Karen L. Kotloff · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $1,382,804 — Novavax CoVPN 3004 Adult and Pediatric Booster Administration Project Summary/Abstract: Novavax Adult and Pediatric booster To date, 485 adult and 29 pediatric participants have received the initial series of vaccinations, had associated follow-up visits, and participated in a blinded cross-over. We…
BRAD H POLLOCK · PUBLIC HEALTH INSTITUTE · 2022 · $1,500,000 — In children, DNA replication repair deficiency (RRD), caused by mutations in the mismatch repair of DNA polymerase genes, is an important cancer mechanism. RRD drives a deadly group of cancers universally characterized by hypermutation, microsatellite instable (MSI) in/dels and resistance to chemora…
Paul Bates · UNIVERSITY OF PENNSYLVANIA · 2022 · $215,821 — Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a pathogenic, tick-transmitted bunyavirus that can cause a severe febrile hemorrhagic-like disease with case fatality rates of up to 30%. Discovered during a 2009 outbreak of febrile illness in China, the geographic distribution of SFTSV e…
Shinji Makino · UNIVERSITY OF TEXAS MED BR GALVESTON · 2022 · $309,206 — Coronaviruses (CoVs), which carry a large, single-stranded, positive-sense RNA genome, cause a variety of diseases in humans and domestic animals. Human CoVs (HCoVs) usually infect the respiratory tract and cause a range of symptoms varying from mild, such as the common cold, to more serious respira…
Elena Vassilieva · EMORY UNIVERSITY · 2022 · $234,750 — PROJECT SUMMARY Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) is currently causing the coronavirus disease (COVID-19) in pandemic proportion. According to John Hopkins university data tracker, there were 120,217,175 global cases and 2,660,456 deaths worldwide on March 15, 2021. The d…
DANIEL G ANDERSON · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2022 · $789,957 — Many HIV vaccine candidates have failed clinical trials, as they were unable to elicit a potent and durable response to HIV viral challenge. Broadly neutralizing antibodies (bnAbs) have been identified in a number of HIV+ individuals with well-controlled viral levels, and these bnAbs target epitopes…